✦ LIBER ✦

The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma

✍ Scribed by David J. Flavell; Sarah L. Warnes; Christine J. Bryson; Sarah A. Field; Armorel L. Noss; Graham Packham; Sopsamorn U. Flavell

Book ID: 108673823
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 548 KB
Volume: 134
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2006.06155.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Experimental treatment of human diffuse

Experimental treatment of human diffuse large B-cell lymphoma xenografts by doxycycline alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab

✍ Franck Assayag; Nicole Brousse; Jérôme Couturier; Elizabeth Macintyre; Claire Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB 👁 2 views

Intralesional and intravenous treatment

Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases

✍ K. Kerl; C. Prins; J.H. Saurat; L.E. French 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

Quality of life during maintenance thera

Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial

✍ Mathias Witzens-Harig; Monika Reiz; Christiane Heiß; Axel Benner; Manfred Hensel 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 139 KB

A dominant linear B-cell epitope of rici

A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin

✍ D. CASTELLETTI; G. FRACASSO; S. RIGHETTI; G. TRIDENTE; R. SCHNELL; A. ENGERT; M. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB